Onconova technologies and products are developed utilizing our proprietary chemistry platform. Our capabilities span drug discovery and early development stages, from medicinal chemistry to Phase 3 clinical trials. We anticipate that some of our product candidates will be partnered with pharmaceutical or biotechnology companies for advanced development. We will endeavor to retain a participating role as we expand our competency horizon to include commercialization capabilities.
To discuss partnering opportunities with Onconova please contact email@example.com.
SYMBIO PHARMACEUTICALS LIMITED
In July 2011 Onconova and Symbio announced that they will collaborate to develop and commercialize rigosertib in Japan and Korea. Under the terms of the agreement, SymBio has an exclusive license for Japan and Korea and will develop and commercialize rigosertib in these countries. Onconova will receive an upfront payment and development milestones tied to the progress of rigosertib, as well as sales milestone payments plus royalties on net sales. The two companies entered into an agreement for the supply of development stage and intend to enter into an agreement for the supply of the commercial product.